Arunjyoti Bio Ventures Limited reported a share acquisition by Chennupati Sarath Kumar under SEBI disclosure requirements. The non-promoter acquired 54,25,516 equity shares representing 2.91% of the company's total capital through open market transactions between April 13-16, 2026, changing his shareholding position in the BSE-listed company.

Arunjyoti Bio Ventures Limited Reports Share Acquisition by Chennupati Sarath Kumar

Arunjyoti bio ventures Limited has filed a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reporting a share acquisition transaction by Chennupati Sarath Kumar. The disclosure, dated April 16, 2026, was submitted to BSE Limited where the company's shares are listed.

Transaction Details

Chennupati Sarath Kumar, who is not part of the promoter or promoter group, acquired shares in the company through open market transactions. The acquisition was executed over a period spanning from April 13, 2026, to April 16, 2026.

Transaction Parameter: Details Shares Acquired: 54,25,516 equity shares Percentage of Total Capital: 2.91% Transaction Mode: Open Market Transaction Period: April 13, 2026 to April 16, 2026 Acquirer Category: Non-Promoter

Shareholding Pattern Changes

The transaction resulted in an increase in Chennupati Sarath Kumar's stake in Arunjyoti Bio Ventures Limited. His shareholding position changed following the completion of the acquisition.

Shareholding Details: Before Acquisition After Acquisition Change Number of Shares: 1,41,01,138 86,75,622 +54,25,516 Percentage Holding: 7.57% 4.66% +2.91%

Company Capital Structure

The company's equity share capital structure remained unchanged following this transaction. Arunjyoti Bio Ventures Limited maintains its existing capital base without any alterations to the total number of shares or their face value.

Capital Structure: Details Total Equity Capital: Rs. 18,63,81,000 Number of Shares: 18,63,81,000 Face Value per Share: Re. 1/- Listing Exchange: BSE Limited Scrip Code: 530881

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations governing substantial acquisition and disposal of shares. The transaction falls under the purview of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which mandates disclosure when shareholding changes exceed specified thresholds. The filing ensures transparency and keeps investors informed about significant changes in shareholding patterns of listed companies.

Arunjyoti Bio Ventures Limited has issued an important regulatory disclosure to BSE Limited regarding unsolicited messages being circulated about the company's scrip. The formal communication, dated April 13, 2026, was made under Regulation 30(11) of SEBI (LODR) Regulations, 2015.

Regulatory Disclosure Details

The company has been informed about instances of unsolicited messages being circulated in relation to Arunjyoti Bio Ventures Limited's scrip. This disclosure represents the company's proactive approach to maintaining transparency and protecting investor interests in compliance with securities regulations.

Parameter: Details Disclosure Date: April 13, 2026 Regulation: SEBI (LODR) Regulations, 2015 - Section 30(11) Exchange: BSE Limited Subject Matter: Unsolicited messages in company scrip

Investor Advisory

In response to these developments, Arunjyoti Bio Ventures Limited has issued a clear advisory to investors. The company has specifically advised investors to take due care and caution while dealing in shares of the company. This precautionary measure aims to protect shareholders from potential misinformation or manipulative activities that may affect trading decisions.

Management Authorization

The disclosure was formally authorized and signed by Pabbathi Badari Narayana Murthy, who serves as the Whole-Time Director of the company. His Director Identification Number (DIN) is 01445523, and the document bears his digital signature along with the official company stamp.

Regulatory Compliance

This disclosure demonstrates the company's commitment to maintaining regulatory compliance and transparency standards as mandated by SEBI regulations. The timely communication to BSE Limited reflects the company's adherence to disclosure norms designed to protect investor interests and maintain market integrity.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.